Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.40 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.37 |
| ▸ | MYC | P01106 | 1/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.36 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.36 |
| ▸ | CCNK | O75909 | 1/20 | 0.36 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL563219 | 0.90 | MAPK14 (0.40) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL562380 | 0.87 | MAPK14 (0.38) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL13091941 | 0.83 | KCNJ5 (0.39) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL10203755 | 0.83 | KCNJ5 (0.39) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL10203732 | 0.82 | MAPK14 (0.40) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL563285 | 0.82 | MAPK14 (0.40) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL6584970 | 0.82 | TMEM97 (0.41) | MAPK14PTGER1TMEM97SIGMAR1KCNJ5 | |
| SCHEMBL6584978 | 0.82 | TMEM97 (0.41) | MAPK14PTGER1TMEM97SIGMAR1KCNJ5 | |
| SCHEMBL13092079 | 0.78 | MAPK14 (0.38) | MAPK14KCNJ5KCNJ3CCNKCDK12 | |
| SCHEMBL14882376 | 0.78 | ALDH1A1 (0.51) | MAPK14TMEM97SIGMAR1KCNJ5KCNJ3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423176-A1 | CARBOXYLIC ACID COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035196-A1 | CARBOXYLIC ACID COMPOUND | GPR119, GPR65, GPR55 | MAPK14 1857/4885PTGER1 2129/4885MYC 703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.